All Stories

  1. Nuclear aging in polyglutamine-induced neurodegeneration
  2. Clock gene signature predicts insomnia and links to sleep/circadian parameters
  3. Tomatidine is a senotherapeutic compound that improves cognitive function and reduces cellular senescence in aged mice
  4. Regulation of Metabolic Rhythms by Glial Clocks
  5. Neuroendocrine timekeepers: changes in normal and premature aging
  6. Circadian rhythms are disrupted in patients and preclinical models of Machado-Joseph disease
  7. The Therapeutic Potential of Melatonin and Its Novel Synthetic Analogs in Circadian Rhythm Sleep Disorders, Inflammation‐Associated Pathologies, and Neurodegenerative Diseases
  8. Abstracts
  9. The (un)known crosstalk between metabolism and mechanotransduction: Implications for metabolic syndrome (MetS)-associated neurological complications
  10. Restoring neuropetide Y levels in the hypothalamus ameliorates premature aging phenotype in mice
  11. Senescent cell transplantation into the skin induces age‐related peripheral dysfunction and cognitive decline
  12. Modeling hypothalamic pathophysiology in vitro for metabolic, circadian, and sleep disorders
  13. Lipodystrophy as a target to delay premature aging
  14. Ghrelin delays premature aging in Hutchinson‐Gilford progeria syndrome
  15. Primary cilia shape hallmarks of health and aging
  16. Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies
  17. Ataxin-2 in the hypothalamus at the crossroads between metabolism and clock genes
  18. The impact of insomnia on frailty and the hallmarks of aging
  19. Obstructive sleep apnea impact on physiology: insights from a mouse model and a case-control study
  20. The impact of obstructive sleep apnea treatment with continuous positive airway pressure on the biological clock
  21. SIRT1 activation and its circadian clock control: a promising approach against (frailty in) neurodegenerative disorders
  22. Peripheral biomarkers to diagnose obstructive sleep apnea in adults: A systematic review and meta-analysis
  23. SIRT2 Deficiency Exacerbates Hepatic Steatosis via a Putative Role of the ER Stress Pathway
  24. PET Imaging of the Neuropeptide Y System: A Systematic Review
  25. A look on food intake and satiety: from humans to rodent models
  26. Skin senescence: mechanisms and impact on whole-body aging
  27. Blueberry Counteracts Prediabetes in a Hypercaloric Diet-Induced Rat Model and Rescues Hepatic Mitochondrial Bioenergetics
  28. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases
  29. The NutriClock Study Protocol - Assessing the Impact of a Chrononutrition Intervention in Patients With Cardiometabolic Disturbances
  30. PI3K/AKT/MTOR and ERK1/2-MAPK signaling pathways are involved in autophagy stimulation induced by caloric restriction or caloric restriction mimetics in cortical neurons
  31. Long-term continuous positive airway pressure treatment ameliorates biological clock disruptions in obstructive sleep apnea
  32. Neuropeptide Y (NPY) intranasal delivery alleviates Machado–Joseph disease
  33. Common risk factors and therapeutic targets in obstructive sleep apnea and osteoarthritis: An unexpectable link?
  34. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  35. The Superpowers of Our Sleep
  36. Blueberry Consumption Challenges Hepatic Mitochondrial Bioenergetics and Elicits Transcriptomics Reprogramming in Healthy Wistar Rats
  37. Trehalose alleviates the phenotype of Machado–Joseph disease mouse models
  38. Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells
  39. Long-Term Continuous Positive Airway Pressure Treatment Ameliorates Biological Clock Disruptions in Obstructive Sleep Apnea
  40. Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases
  41. The importance of determining circadian parameters in pharmacological studies
  42. In vitro susceptibility of Trypanosoma brucei brucei to selected essential oils and their major components
  43. Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice
  44. Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis
  45. Role of Beta-adrenergic Receptors and Sirtuin Signaling in the Heart During Aging, Heart Failure, and Adaptation to Stress
  46. Obstructive Sleep Apnea and Hallmarks of Aging
  47. The NAD+-dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes
  48. Quizzes as an active learning strategy: A study with students of pharmaceutical sciences
  49. Unraveling the Role of Ataxin-2 in Metabolism
  50. Hypoxia mimetic induces lipid accumulation through mitochondrial dysfunction and stimulates autophagy in murine preadipocyte cell line
  51. Hypothalamic Dysfunction in Obesity and Metabolic Disorders
  52. Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases
  53. Caloric restriction stimulates autophagy in rat cortical neurons through neuropeptide Y and ghrelin receptors activation
  54. The pathophysiology of defective proteostasis in the hypothalamus — from obesity to ageing
  55. Antileishmanial activity of antiretroviral drugs combined with miltefosine
  56. Corrigendum to “Intracellular mechanisms coupled to NPY Y2 and Y5 receptor activation and lipid accumulation in murine adipocytes” [neuropeptides 46/6 (2012) 359–366]
  57. Caloric restriction blocks neuropathology and motor deficits in Machado–Joseph disease mouse models through SIRT1 pathway
  58. The Adenosinergic System in Diabetic Retinopathy
  59. Neuropeptide Y: An Anti-Aging Player?
  60. Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism
  61. Impaired adrenal medullary function in a mouse model of depression induced by unpredictable chronic stress
  62. Activation of Neuropeptide Y Receptors Modulates Retinal Ganglion Cell Physiology and Exerts Neuroprotective ActionsIn Vitro
  63. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado–Joseph disease
  64. Neuropeptide Y system in the retina: From localization to function
  65. NPY/neuropeptide Y enhances autophagy in the hypothalamus: a mechanism to delay aging?
  66. Neuropeptide Y stimulates autophagy in hypothalamic neurons
  67. Hypothalamic involvement in premature aging laminopathies
  68. Alterations in phospholipidomic profile in the brain of mouse model of depression induced by chronic unpredictable stress
  69. Fluoxetine Induces Proliferation and Inhibits Differentiation of Hypothalamic Neuroprogenitor Cells In Vitro
  70. Role of hypothalamic neurogenesis in feeding regulation
  71. MicroRNAs in Obesity and Metabolism
  72. Catecholamine Release Modulation by Adenosine Through A2a Receptors in Mouse Chromaffin Cells in Culture
  73. Catecholamine Release Modulation by Adenosine through A2AReceptors in Mouse Chromaffin Cell Culture
  74. Chronic Unpredictable Stress Induces Catecholaminergic System Changes in Mouse Adrenal Gland
  75. Emerging novel roles of neuropeptide Y in the retina: From neuromodulation to neuroprotection
  76. Progenitor Cells in Chromospheres: In Response to Arthur S. Tischler
  77. Effect of Diabetes/Hyperglycemia on the Rat Retinal Adenosinergic System
  78. Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate
  79. Neuropeptide Y Receptors Y 1 and Y 2 are Present in Neurons and Glial Cells in Rat Retinal Cells in Culture
  80. Intracellular mechanisms coupled to NPY Y2 and Y5 receptor activation and lipid accumulation in murine adipocytes
  81. Isolation, Characterization, and Differentiation of Progenitor Cells from Human Adult Adrenal Medulla
  82. Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression
  83. Contribution of TNF receptor 1 to retinal neural cell death induced by elevated glucose
  84. Regulation of catecholamine release in human adrenal chromaffin cells by β-adrenoceptors
  85. Effects of 3,4-Methylenedioxymethamphetamine Administration on Retinal Physiology in the Rat
  86. Moderate Long-Term Modulation of Neuropeptide Y in Hypothalamic Arcuate Nucleus Induces Energy Balance Alterations in Adult Rats
  87. Proliferative Hypothalamic Neurospheres Express NPY, AGRP, POMC, CART and Orexin-A and Differentiate to Functional Neurons
  88. Neuropeptide Y inhibits [Ca2+]ichanges in rat retinal neurons through NPY Y1, Y4, and Y5receptors
  89. Regulation of catecholamine release and tyrosine hydroxylase in human adrenal chromaffin cells by interleukin-1β: role of neuropeptide Y and nitric oxide
  90. Neuropeptide Y Family Peptides
  91. Stress-Induced Hypertension and Increased Sympathetic Activity in Mice Overexpressing Neuropeptide Y in Noradrenergic Neurons
  92. Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia
  93. Neuropeptide Y stimulates retinal neural cell proliferation - involvement of nitric oxide
  94. Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy
  95. Intracellular signaling mechanisms mediating catecholamine release upon activation of NPY Y1receptors in mouse chromaffin cells
  96. NPY in rat retina is present in neurons, in endothelial cells and also in microglial and Müller cells
  97. NPY Y1 receptor is not involved in the hemodynamic response to an acute cold pressor test in mice
  98. Neuropeptide Y regulates catecholamine release evoked by interleukin-1β in mouse chromaffin cells
  99. Deletion of the neuropeptide Y (NPY) Y 1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion
  100. The Putative Neuroprotective Role of Neuropeptide Y in the Central Nervous System
  101. Neuropeptide Y expression, localization and cellular transducing effects in HUVEC
  102. Up-regulation of neuropeptide Y levels and modulation of glutamate release through neuropeptide Y receptors in the hippocampus of kainate-induced epileptic rats
  103. NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-α and IFN-γ in HUVEC
  104. Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in mice
  105. Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor
  106. Neuropeptide Y and its receptors as potential therapeutic drug targets
  107. Catecholamine and Neuropeptide Y Secretion from Human Adrenal Chromaffin Cells
  108. Differential Secretion of Catecholamine and Neuropeptide Y in Response to KCl from Mice Chromaffin Cells
  109. Dibasic cleavage site is required for sorting to the regulated secretory pathway for both pro- and neuropeptide Y
  110. Interplay Between Galanin and Leptin in the Hypothalamic Control of Feeding via Corticotropin-Releasing Hormone and Neuropeptide Y
  111. NPY Regulates Catecholamine Secretion from Human Adrenal Chromaffin Cells
  112. Cardiovascular effects of fentanyl in conscious rats
  113. In vitro study of the interaction of Tilia europeae L. aqueous extract with GABAA receptors in rat brain